Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
Erasca (ERAS) Stock Price & Analysis
216 Followers
ERAS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.51 - $3.38
Previous Close$1.9
Volume357.30K
Average Volume (3M)803.51K
Market Cap
$329.38M
Enterprise Value$72.89M
Total Cash (Recent Filing)$312.35M
Total Debt (Recent Filing)$55.86M
Price to Earnings (P/E)-2.3
Beta1.88
Next Earnings
Aug 08, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding173,358,966
10 Day Avg. Volume550,598
30 Day Avg. Volume803,507
Standard Deviation0.19
R-Squared0.09
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)1.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$18.80Price Target Upside889.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Erasca News
PremiumCompany Announcements
Erasca Secures Funding for Future Growth Through Private Placement
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementFast Track Designation for Naporafenib is a validation of the clinical program, indicating potential expedited development and review for the treatment of NRAS mutated melanoma.
Financial StabilityThe extension of the company's cash runway into the first half of 2026 enhances financial stability, supporting ongoing research and development efforts.
Regulatory MilestoneFDA alignment on the pivotal naporafenib trial in NRAS melanoma, along with agreed trial design for SEACRAFT-2, marks a significant step in advancing the drug's development.
Bears Say
Clinical Trial SetbackThe discontinuation of the ERAS-601+cetuximab study could negatively impact investor sentiment.
Research And DevelopmentRemoval of ERAS-601+cetuximab from the company's valuation reflects a setback in its development pipeline.
Valuation AdjustmentAnalyst lowers the price target (PT) on ERAS to $7 from $8 due to the exclusion of ERAS-601+cetuximab from their valuation.
---
Ownership Overview
32.18% Insiders
6.50% Mutual Funds
9.78% Other Institutional Investors
51.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.51 and its highest was $3.38 in the past 12 months.
What is Erasca’s market cap?
Currently, no data Available
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Aug 08, 2024 which is in 86 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on May 09, 2024. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.028.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -$0.22.
How many shares outstanding does Erasca have?
Erasca has 173,358,960 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went down -8.837%.
Which hedge fund is a major shareholder of Erasca?
Among the largest hedge funds holding Erasca’s share is Woodline Partners LP. It holds Erasca’s shares valued at 2M.
---
Erasca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.80 (889.47% Upside)
$18.80 (889.47% Upside)
Hedge Fund Trend
Increased
By 880.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.79%
12-Months-Change
Fundamentals
Return on Equity
-37.60%
Trailing 12-Months
Asset Growth
-20.86%
Trailing 12-Months
Company Description
Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.
---
ERAS Earnings Call
Q4 2024
0:00 / 0:00
---
ERAS Stock 12 Month Forecast
Average Price Target
$18.80
▲(889.47% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Arvinas Holding Company
―
Oncolytics Biotech
―
Meiragtx Holdings
―
Best Analysts Covering ERAS
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-8.45%
reiterated a buy rating 6 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -8.45% per trade.
---